Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

30,218 total articles

Point72 Hires Industry Veteran to Explore External Alpha-Capture Program

Point72 Hires Industry Veteran to Explore External Alpha-Capture Program

Point72 Asset Management has recruited alpha-capture specialist Ricky Nardis to help evaluate and potentially build a program that gathers trading insights from other hedge funds. The initiative is in an exploratory phase, and the firm’s plans may change. Similar efforts are being prepared at Citadel, and the approach builds on a model pioneered by…

William Blair: Blue Origin’s Path Back to Flight Seen as Tailwind for AST SpaceMobile and Karman

William Blair: Blue Origin’s Path Back to Flight Seen as Tailwind for AST SpaceMobile and Karman

William Blair says Blue Origin’s anticipated resumption of launches this year offers upside to AST SpaceMobile and Karman after the New Glenn launchpad explosion. Company executives and analysts outlined expectations at William Blair’s 46th Annual Growth Stock Conference, where both AST SpaceMobile and Karman reiterated operational targets and reve…

BofA: Bond Funds See Largest Weekly Inflows Since June 2020

BofA: Bond Funds See Largest Weekly Inflows Since June 2020

Bank of America reports that fixed income funds experienced their strongest weekly inflows in six years, reaching levels not observed since June 2020. The buying was broad-based across investment-grade, high-yield, government, loan, emerging market and money-market strategies, extending a multi-week trend of investor preference for debt instruments…

TD Cowen Lifts 2030 Global GLP-1 Sales Forecast to $150 Billion

TD Cowen Lifts 2030 Global GLP-1 Sales Forecast to $150 Billion

TD Cowen has upgraded its estimate for global sales of GLP-1 therapies to $150 billion by 2030, up from $139 billion, and now anticipates about 59 million patients receiving treatment by that year. The firm expects oral weight-loss formulations to secure a larger slice of the market and projects continued dominance by Eli Lilly and Novo Nordisk.